Stevanato Group S.p.A. (STVN) experienced a significant pre-market surge of 14.92% on Wednesday, following the release of its fourth-quarter and full-year 2025 financial results.

The pharmaceutical services company reported quarterly adjusted earnings of €0.18 per share, exceeding analyst estimates of €0.17. Revenue for the quarter rose to €346.5 million, a 4.8% year-over-year increase that also beat the consensus expectation of €333.01 million. The strong performance was driven by a 31% jump in revenue from high-value solutions, which reached a record €171.4 million and represented 49% of total Q4 revenue.

For fiscal year 2026, Stevanato Group provided guidance that includes revenue in the range of €1.26 billion to €1.29 billion and adjusted diluted EPS between €0.59 and €0.63. The company's Biopharmaceutical and Diagnostic Solutions segment showed particular strength with 10% revenue growth, while management highlighted that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025.